Charles K. Gayer

Charles K. Gayer

President and Chief Executive Officer; Former Chief Commercial OfficeratBiocryst Pharmaceuticals· In proxies 2022–2025

Pay in FY2025+185% from the year before · Biocryst Pharmaceuticals stock +3.7% the same year

Charles K. Gayer was paid $9.6M in FY2025 (Dec), up 185%. Biocryst Pharmaceuticals stock rose 3.7% that year.

Pay$100 in the stock at the end of FY21 → $56
Pay is from the Summary Compensation Table of each Biocryst Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Biocryst PharmaceuticalsPublic company · 4 yr
    • President and Chief Executive Officer; Former Chief Commercial Officer2022 – Present · 4 yrStock in role -39%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?